Physician profile
Thomas M Stank
NPI 1598779209
$16,055.38
in general payments reported to CMS, 2019-2025
33 companies · $691 in 2025
The $691 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $205 · 2021: $822 · 2022: $910 · 2023: $1,101 · 2024: $800 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,487 · Entertainment: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,487.21 |
| Entertainment | $105.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $11,166.56 | 2019 | |
| Abbvie INC. | $971.12 | 2022-2025 | Durysta, Xen Glaucoma Treatment System, Ozurdex |
| Allergan, INC. | $654.94 | 2019-2022 | |
| Sight Sciences, INC. | $518.64 | 2019-2025 | Omni Surgical System |
| Biotissue Holdings INC. | $430.07 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $404.73 | 2021-2025 | Acthar |
| Alcon Vision LLC | $352.64 | 2019-2025 | Clareon, Centurion, Hydrus Microstent |
| Bausch & Lomb Americas INC. | $250.34 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Johnson & Johnson Surgical Vision, INC. | $200.47 | 2019-2024 | Tecnis Iol, Tecnis Iol |
| Novartis Pharmaceuticals Corporation | $169.04 | 2019-2023 | |
| Optos, INC. | $153.08 | 2020-2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Oyster Point Pharma, INC. | $126.71 | 2022-2024 | Tyrvaya, Ryzumvi |
| Amgen INC. | $92.65 | 2024-2025 | Tepezza |
| Shire North American Group INC | $80.91 | 2019 | |
| Ivantis, INC | $52.13 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $52.05 | 2023-2024 | Eylea Hd |
| Rayner Intraocular Lenses Limited | $50.65 | 2022-2023 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Glaukos Corporation | $46.25 | 2020-2025 | Istent Trabecular Micro-Bypass System Model Is3, Idosetr |
| Eyepoint US, INC. | $27.79 | 2019 | |
| Kala Pharmaceuticals, INC. | $25.96 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $23.24 | 2022 | |
| Genentech USA, INC. | $22.71 | 2023 | Vabysmo |
| Harrow Eye, LLC | $21.64 | 2024 | Vevye |
| Tarsus Pharmaceuticals, INC. | $19.85 | 2025 | Xdemvy |
| Horizon Therapeutics Plc | $18.68 | 2023 | |
| Ocular Therapeutix, INC. | $17.58 | 2021 | |
| Rxsight INC | $17.44 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Ani Pharmaceuticals, INC. | $15.78 | 2025 | Purified Cortrophin Gel |
| Aerie Pharmaceuticals, INC. | $15.27 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.10 | 2019 | |
| Omeros Corporation | $14.57 | 2021 | |
| Eyevance Pharmaceuticals LLC | $13.81 | 2019 | |
| Vyera Pharmaceuticals, LLC | $12.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Stank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.